AzTrials
AzTrials

Cheek WrinklesNCT04124692

Safety and Effectiveness of Sculptra Aesthetic for Correction of Cheek Wrinkles

A study testing Sculptra Aesthetic new dilution in people with Cheek Wrinkles, run by Galderma R&D at 13 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The study has been designed to evaluate the safety and effectiveness of Sculptra Aesthetic as a single regimen for correction of cheek wrinkles after changes in reconstitution and injection procedures compared to the approved label. Read more about this study

Who is it for?
Ages 21 years and olderHealthy volunteers can take part
Conditions the study is for
Cheek Wrinkles
What is being tested?
Sculptra Aesthetic new dilution
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
149 participants
Where
13 sitesUnited States
Study dates
12 Nov 2019to 12 Aug 2021
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Intent to undergo correction of cheek wrinkles on both sides of the face and a Galderma Cheek Wrinkles Scale (GCWS) At Rest score of Moderate or Severe on EACH side of the face.

Who cannot join

  • Known/previous allergy or hypersensitivity to any of the Sculptra Aesthetic constituents.
  • Previous tissue augmenting therapy, contouring or revitalization treatment in the face, except the lips, with any of the following fillers prior to Baseline visit:
  • Collagen, Hyaluronic Acid - 12 months
  • Calcium Hydroxyapatite (CaHa), Poly L- Lactic Acid (PLLA) or permanent (nonbiodegradable)- Prohibited

Trial locations and contacts

13 sites in 1 country.

13 sites in 1 country

United States13 sites
  • Galderma Research Site

    Alpharetta, Georgia, 30022

  • Galderma Research Site

    Coral Gables, Florida, 33143

  • Galderma Research Site

    Dallas, Texas, 75254

  • Galderma Research Site

    Encino, California, 91436

  • Galderma Research Site

    New Orleans, Louisiana, 70115

  • Galderma Research Site

    New York, New York, 10021

  • Galderma Research Site

    New York, New York, 10028

  • Galderma Research Site

    Redondo Beach, California, 90277

  • Galderma Research Site

    Rockville, Maryland, 20852

  • Galderma Research Site

    San Diego, California, 92121

  • Galderma Research Site

    Scottsdale, Arizona, 85255

  • Galderma Research Site

    Spring, Texas, 77388

  • Galderma Research Site

    Washington D.C., District of Columbia, 20037

Other trials in United States

About this study

Official title: A Randomized, Evaluator-blinded, No-treatment Controlled, Multicenter Study to Evaluate the Effectiveness and Safety of Sculptra Aesthetic for Correction of Cheek Wrinkles.

The study has been designed to evaluate the safety and effectiveness of Sculptra Aesthetic as a single regimen for correction of cheek wrinkles after changes in reconstitution and injection procedures compared to the approved label.

Conditions
Cheek Wrinkles
Being tested
Sculptra Aesthetic new dilution

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Sculptra Aesthetic new dilutionDevice

    Treatment of cheek wrinkles

Study groups in NCT04124692
Study groupRoleWhat they receive
Control Group: No-treatmentNo interventionParticipants will receive no treatment during the study.
Treatment Group: Sculptra AestheticExperimentalParticipants will be injected with Sculptra Aesthetic by Treating Investigator at Day 1 until optimal correction achieved (up to 4 total treatment sessions)
Receives: Device: Sculptra Aesthetic new dilution

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Responder Rate Based on the Blinded Evaluator's Live Assessment of the Galderma Cheek Wrinkles Scale (GCWS) at Rest at Month 12

    Responder rate was defined as the percentage of participants with at least a 1-grade improvement from baseline on the GCWS, on both sides of the face, concurrently. GCWS is a validated 5-point scale used to assess the severity of cheek wrinkles: 0 (none [no lines or wrinkles]), 1 (mild [only few superficial lines]), 2 (moderate [many superficial lines or a few shallow wrinkles]), 3 (severe [many shallow wrinkles or a few moderate depth wrinkles]) and 4 (very severe [many moderate wrinkles or at least one depth wrinkle with or without redundant folds]). Higher score means more severe (worse) wrinkles. The participant was to have a relaxed face during the assessment.

    Measured: At Month 12

Secondary outcomes (21)
  1. Responder Rate Based on the Blinded Evaluator's Live Assessment of the GCWS at Rest at Months 7 and 9

    Responder rate was defined as the percentage of participants with at least a 1-grade improvement from baseline on the GCWS, on both sides of the face, concurrently. GCWS is a validated 5-point scale used to assess the severity of cheek wrinkles: 0 (none [no lines or wrinkles]), 1 (mild [only few superficial lines]), 2 (moderate [many superficial lines or a few shallow wrinkles]), 3 (severe [many shallow wrinkles or a few moderate depth wrinkles]) and 4 (very severe [many moderate wrinkles or at least one depth wrinkle with or without redundant folds]). Higher score means more severe (worse) wrinkles. The participant was to have a relaxed face during the assessment.

    Measured: At Months 7 and 9

  2. Responder Rate Based on the Blinded Evaluator's Live Assessment of the GCWS Dynamic at Months 7, 9 and 12

    Responder rate was defined as the percentage of participants with at least a 1-grade improvement from baseline on the GCWS, on both sides of the face, concurrently. GCWS is a validated 5-point scale used to assess the severity of cheek wrinkles: 0 (none [no lines or wrinkles]), 1 (mild [only few superficial lines]), 2 (moderate [many superficial lines or a few shallow wrinkles]), 3 (severe [many shallow wrinkles or a few moderate depth wrinkles]) and 4 (very severe [many moderate wrinkles or at least one depth wrinkle with or without redundant folds]). Higher score means more severe (worse) wrinkles. The participant was to have a closed maximum smile during the assessment.

    Measured: At Months 7, 9, and 12

  3. Percentage of Participants With Improvement Rate Based on the Independent Photographic Reviewer's Assessment

    Improvement rate based on the Independent Photographic Reviewer's assessment using random pairings of baseline and Month 12 photographs was done.

    An improved subject is defined as a subject for whom the Independent Photographic Reviewer identified the month 12 photograph in the pair as post-treatment.

    Measured: At Month 12

  4. Percentage of Participants With At Least "Improved" on the Global Aesthetic Improvement Scale (GAIS) Based on the Participants Live Assessment

    GAIS responder rates are based on independent assessments by the participant. Responder rate was defined as the percentage of participants with at least "Improved" when compared to baseline before first treatment. The 7-graded GAIS was used by the participant to live assess the aesthetic improvement of the cheek wrinkles by responding to the question: "How would you describe the aesthetic improvement today compared to the photograph taken before treatment?" by using the respective categorical scale as follows; Very Much Improved, Much Improved, Improved, No Change, Worse, Much Worse, Very Much Worse.

    Measured: At Months 7, 9, and 12

  5. Percentage of Participants With At Least "Improved" on the GAIS Based on the Investigator Live Assessment

    GAIS responder rates are based on independent assessments by the investigator. Responder rate was defined as the percentage of participants with at least "Improved" when compared to baseline before first treatment. The 7-graded GAIS was used by the investigator to live assess the aesthetic improvement of the cheek wrinkles by responding to the question: "How would you describe the aesthetic improvement today compared to the photograph taken before treatment?" by using the respective categorical scale as follows; Very Much Improved, Much Improved, Improved, No Change, Worse, Much Worse, Very Much Worse.

    Measured: At Months 7, 9, and 12

  6. Satisfaction With Treatment: Does the Treatment Make You Look Younger?

    A 5-point subject satisfaction questionnaire with the following responses: Excellent, Very good, Good, Satisfactory, Not satisfied.

    Measured: At Months 7, 9, and 12

  7. Satisfaction With Treatment: Does the Treatment Make You Feel Better About Yourself?

    A 5-point subject satisfaction questionnaire with the following responses: Excellent, Very good, Good, Satisfactory, Not satisfied.

    Measured: At Months 7, 9, and 12

  8. Satisfaction With Treatment: Does the Treatment Improve Your Self-confidence?

    A 5-point subject satisfaction questionnaire with the following responses: Excellent, Very good, Good, Satisfactory, Not satisfied.

    Measured: At Months 7, 9, and 12

  9. Satisfaction With Treatment: Does the Treatment Improve Overall Satisfaction With Your Appearance?

    A 5-point subject satisfaction questionnaire with the following responses: Excellent, Very good, Good, Satisfactory, Not satisfied.

    Measured: At Months 7, 9, and 12

  10. Satisfaction With Treatment: Does the Treatment Make You Look/Feel More Confident in Your Life?

    A 5-point subject satisfaction questionnaire with the following responses: Excellent, Very good, Good, Satisfactory, Not satisfied.

    Measured: At Months 7, 9, and 12

  11. Satisfaction With Treatment: Does the Treatment Make You Look the Way You Feel?

    A 5-point subject satisfaction questionnaire with the following responses: Excellent, Very good, Good, Satisfactory, Not satisfied.

    Measured: At Months 7, 9, and 12

  12. Satisfaction With Treatment: Does the Treatment Improve Your Skin Firmness?

    A 5-point subject satisfaction questionnaire with the following responses: Excellent, Very good, Good, Satisfactory, Not satisfied.

    Measured: At Months 7, 9, and 12

  13. Satisfaction With Treatment: Does the Treatment Improve Your Skin Radiance?

    A 5-point subject satisfaction questionnaire with the following responses: Excellent, Very good, Good, Satisfactory, Not satisfied.

    Measured: At Months 7, 9, and 12

  14. Satisfaction With Treatment: Does the Treatment Improve Your Skin Sagging?

    A 5-point subject satisfaction questionnaire with the following responses: Excellent, Very good, Good, Satisfactory, Not satisfied.

    Measured: At Months 7, 9, and 12

  15. Satisfaction With Treatment: Does the Treatment Make Your Skin Look More Refreshed?

    A 5-point subject satisfaction questionnaire with the following responses: Excellent, Very good, Good, Satisfactory, Not satisfied.

    Measured: At Months 7, 9, and 12

  16. Subject Satisfaction: Would You Say That the Treatment Results Are Natural Looking?

    A 5-point subject satisfaction questionnaire with the following responses: Strongly agree, Agree, Neither agree or Disagree, Disagree, Strongly disagree.

    Measured: At Months 7, 9, and 12

  17. Subject Satisfaction: Would You Say the Subtle Changes Over Time Was Worth It?

    A 5-point subject satisfaction questionnaire with the following responses: Strongly agree, Agree, Neither agree or Disagree, Disagree, Strongly disagree.

    Measured: At Months 7, 9, and 12

  18. Subject Satisfaction: Would You Recommend the Treatment to a Friend?

    A subject satisfaction question with responses Yes or No.

    Measured: At Month 12

  19. Subject Satisfaction: Would You do the Treatment Again?

    A subject satisfaction question with responses Yes or No.

    Measured: At Month 12

  20. Change From Baseline in Satisfaction With Cheeks FACE-Q™ Questionnaire Rasch-transformed Total Scores

    The participant assessed satisfaction using the 5 questions on the FACE-Q: Satisfaction with Cheeks Appearance questionnaire measured on a 4-point scale where 1=very dissatisfied, 2=somewhat dissatisfied, 3=somewhat satisfied, and 4=very satisfied. The responses to the items were converted to a 100-point Rasch transformed total score with 0 (worst) to 100 (best). Higher scores indicate higher satisfaction. A negative change from baseline indicates less improvement.

    Measured: Treatment group: Baseline, Months 1, 2, 3, 7, 9 and 12; Control group: Baseline, Months 7, 9 and 12

  21. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

    An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. TEAEs were defined as AEs with a start date on or after the first dose of investigational product or a start date before the date of the first dose of investigational product that increased in severity or after the date of the first dose. A SAE was any untoward medical occurrence (whether considered to be related to investigational product or not) that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality/birth defect, and was an important medical event. TEAEs included both serious and non-serious TEAEs.

    Measured: From start of study drug administration up to end of the study (up to Month 12)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Oct 2019
  2. Study start12 Nov 2019
  3. Primary completion12 Aug 2021
  4. Study completion12 Aug 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
149 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04124692
Sponsor's protocol ID
43USSA1812
Status last verified
Nov 2023
First submitted
10 Oct 2019
Last updated
18 Nov 2023
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Publications

  • Fabi SG, Le JHTD, Prygova I, Brasater D. Midface Projection Using Biostimulatory Poly- l -Lactic Acid Injectable Implant: A Subgroup Analysis of the Cheek Wrinkle Trial. Dermatol Surg. 2024 Dec 1;50(12):1137-1142. doi: 10.1097/DSS.0000000000004434. Epub 2024 Oct 17.

    PubMed 39453400

Questions about this trial

What is this clinical trial studying?

A study testing Sculptra Aesthetic new dilution in people with Cheek Wrinkles, run by Galderma R&D at 13 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 13 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 18 Nov 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Responder Rate Based on the Blinded Evaluator's Live Assessment of the Galderma Cheek Wrinkles Scale (GCWS) at Rest at Month 12 (time frame: At Month 12). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04124692, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in